CRNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Crinetics Pharmaceuticals Inc (CRNX) does not present a compelling buy opportunity for a beginner, long-term investor at this moment. While the company has promising developments in its pipeline and hedge funds are showing interest, the technical indicators are neutral, options sentiment leans bearish, and the financials indicate significant losses despite some improvement. The lack of strong trading signals and recent downward price movement further suggest holding off on investment.
The MACD is positive but contracting, RSI is neutral at 55.21, and moving averages are converging, indicating no clear trend. The stock is trading near its resistance level (R1: 40.17) and above its pivot point (38.409), suggesting limited upward potential in the short term.
Hedge funds have increased their buying activity by 448.61% over the last quarter. Analysts maintain positive ratings with price targets significantly above the current price, and the company's pipeline execution is steady.
Insiders are neutral with no significant trading activity. The stock has a 60% chance of declining in the short term based on candlestick analysis. Financials show a significant net loss (-$122.8M) and declining gross margin (-17.46% YoY). Options sentiment is bearish, and there is no recent congress trading data to suggest influential interest.
In Q4 2025, revenue remained flat at $6.16M, while net income improved but remained negative at -$122.8M (up 52.39% YoY). EPS improved to -1.29 (up 46.59% YoY), but gross margin dropped to 82.54% (-17.46% YoY), indicating cost pressures.
Analysts remain optimistic with Buy and Outperform ratings, though price targets have been slightly lowered recently (e.g., from $105 to $96 and $84 to $83). The Palsonify launch is progressing steadily, supporting long-term growth potential.
